ADPT Adaptive Biotechnologies Corporation Stock Quote

ADPT [NASD]

Adaptive Biotechnologies Corporation

Index	-	P/E	-	EPS (ttm)	-1.11	Insider Own	1.60%	Shs Outstand	137.00M	Perf Week	3.98%
Market Cap	5.99B	Forward P/E	-	EPS next Y	-1.57	Insider Trans	-79.63%	Shs Float	128.95M	Perf Month	-6.62%
Income	-146.20M	PEG	-	EPS next Q	-0.41	Inst Own	82.50%	Short Float	3.34%	Perf Quarter	-35.98%
Sales	98.40M	P/S	60.88	EPS this Y	-100.60%	Inst Trans	3.26%	Short Ratio	4.12	Perf Half Y	-19.00%
Book/sh	5.43	P/B	7.74	EPS next Y	9.80%	ROA	-14.80%	Target Price	64.80	Perf Year	48.73%
Cash/sh	4.83	P/C	8.70	EPS next 5Y	8.20%	ROE	-22.50%	52W Range	27.28 - 71.25	Perf YTD	-28.92%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-20.60%	52W High	-43.12%	Beta	-
Dividend %	-	Quick Ratio	6.80	Sales past 5Y	-	Gross Margin	77.10%	52W Low	48.57%	ATR	2.63
Employees	622	Current Ratio	6.90	Sales Q/Q	24.80%	Oper. Margin	-	RSI (14)	43.55	Volatility	5.49% 6.09%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-97.70%	Profit Margin	-	Rel Volume	0.46	Prev Close	42.03
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 05 AMC	Payout	-	Avg Volume	1.04M	Price	40.53
Recom	1.70	SMA20	-0.70%	SMA50	-16.05%	SMA200	-16.86%	Volume	189,757	Change	-3.57%

Mar-03-21

Downgrade

Goldman

Buy → Neutral

$74 → $63

Oct-08-20

Resumed

BTIG Research

Buy

$60

Sep-09-20

Initiated

Morgan Stanley

Equal-Weight

$42

Jun-03-20

Initiated

Goldman

Buy

$60

Jul-23-19

Initiated

BTIG Research

Buy

$46

Jul-22-19

Initiated

William Blair

Outperform

Jul-22-19

Initiated

Guggenheim

Buy

$47

Jul-22-19

Initiated

Goldman

Neutral

$32

Jul-22-19

Initiated

Cowen

Outperform

Jul-22-19

Initiated

BofA/Merrill

Buy

$45

Apr-12-21 04:05PM	Adaptive Biotechnologies to Report First Quarter Financial Results on May 5, 2021 GlobeNewswire
01:08AM	What Type Of Shareholders Make Up Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Registry? Simply Wall St.
Mar-17-21 04:05PM	Adaptive Biotechnologies Strengthens Expertise and Diversity of Board of Directors with Appointments of Leslie Trigg and Katey Owen GlobeNewswire
Mar-08-21 11:08AM	FDA Authorizes New Category of Covid-19 Test Barrons.com -9.71%
09:12AM	Looking Into Adaptive Biotechnologies's Return On Capital Employed Benzinga
07:45AM	FDA authorizes Adaptive's T-cell test for people who have already had COVID-19 MarketWatch
05:34AM	Adaptive Biotechnologies Secures FDA EUA For COVID-19 T-Cell Response Test Benzinga
04:05AM	Adaptive Biotech COVID Blood Test Cleared for Emergency Use TheStreet.com
03:30AM	Premarket Movers Monday - GameStop, Athene, Adaptive Biotech TheStreet.com
Mar-07-21 02:52AM	Adaptives T-Detect COVID Test Cleared For Emergency Use In US; Shares Pop 18% SmarterAnalyst
Mar-05-21 06:44PM	Adaptive Biotechnologies Announces FDA Emergency Use Authorization for T-Detect COVID to Confirm Recent or Prior COVID-19 Infection GlobeNewswire
Feb-27-21 02:30PM	Billionaire Julian Robertson On Interest Rates and His Top Stock Picks For 2021 Insider Monkey
Feb-25-21 04:05PM	Adaptive Biotechnologies to Present at the Cowen 41st Annual Healthcare Conference GlobeNewswire -5.27%
Feb-24-21 11:00PM	Adaptive Biotechnologies Corporation (ADPT) Q4 2020 Earnings Call Transcript Motley Fool
05:32PM	Adaptive Biotechnologies: Q4 Earnings Insights Benzinga
04:05PM	Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire
Feb-23-21 12:42PM	Adaptive Bio Launches T-Cell Based COVID-19 Tests Benzinga
09:15AM	Adaptive Biotechnologies Expands Collaboration with Labcorp to Increase Access to Growing Research and Clinical Diagnostic Portfolio GlobeNewswire
07:30AM	Adaptive Biotechnologies Launches T-Detect COVID, First Clinical T-Cell Based Test for Patients to Confirm Recent or Prior COVID-19 Infection GlobeNewswire
Feb-10-21 11:25PM	Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Invest In Growth Simply Wall St.
Feb-02-21 04:05PM	Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021 GlobeNewswire +7.47%
Feb-01-21 09:14AM	New Strong Sell Stocks for February 1st Zacks
Jan-21-21 09:00AM	New Strong Sell Stocks for January 21st Zacks
Jan-18-21 09:12AM	New Strong Sell Stocks for January 18th Zacks
Jan-12-21 08:15AM	The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue Benzinga
Jan-11-21 04:01PM	Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics GlobeNewswire
Jan-06-21 10:53AM	Billionaire Andreas Halvorsens Top 10 Stock Picks Insider Monkey
Dec-30-20 04:30PM	Adaptive Biotechnologies to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
08:51AM	Do Options Traders Know Something About Adaptive Biotechnologies (ADPT) Stock We Don't? Zacks
Dec-06-20 10:00AM	Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of clonoSEQ® Assay on Patients with Blood Cancers at the 62nd ASH Annual Meeting GlobeNewswire
Nov-23-20 08:00AM	Adaptive Biotechnologies and Collaborators to Present Data from More Than 35 Abstracts at ASH 2020 Highlighting Clinical Relevance of MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients GlobeNewswire
Nov-19-20 06:32AM	5 Under-the-Radar Tickers That Will Stomp the Market in 2021 Motley Fool -6.11%
Nov-13-20 08:00AM	Preliminary Data from Real-World Study Demonstrate T-cell Testing Outperforms Antibody Testing in Identifying Past SARS-CoV-2 Infections GlobeNewswire
Nov-11-20 05:21AM	Does Adaptive Biotechnologies' (NASDAQ:ADPT) Share Price Gain of 66% Match Its Business Performance? Simply Wall St. +10.33%
05:00AM	Adaptive Biotechnologies Corporation (ADPT) Q3 2020 Earnings Call Transcript Motley Fool
Nov-10-20 05:25PM	Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Tops Revenue Estimates Zacks
05:22PM	Recap: Adaptive Biotechnologies Q3 Earnings Benzinga
04:13PM	Adaptive Biotechnologies Announces Collaboration with GSK to Measure Minimal Residual Disease with clonoSEQ® Assay Across its Hematology and Oncology Portfolio GlobeNewswire
04:10PM	Adaptive Biotechnologies Reports Third Quarter 2020 Financial Results GlobeNewswire
Nov-03-20 12:30PM	Earnings Preview: Adaptive Biotechnologies (ADPT) Q3 Earnings Expected to Decline Zacks +5.19%
Oct-28-20 05:30PM	Amgen Earnings, Sales Top Wall Street Views; Hikes Earnings Guidance Investor's Business Daily
Oct-13-20 04:05PM	Adaptive Biotechnologies to Report Third Quarter Financial Results on November 10, 2020 GlobeNewswire
Sep-28-20 10:52AM	Do Hedge Funds Love Adaptive Biotechnologies Corporation (ADPT)? Insider Monkey
Sep-01-20 04:03PM	Adaptive Biotechnologies to Present at the Morgan Stanley 2020 Healthcare Conference GlobeNewswire
Aug-11-20 01:01AM	Adaptive Biotechnologies Corporation (ADPT) Q2 2020 Earnings Call Transcript Motley Fool
Aug-10-20 06:35PM	Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM	Adaptive Biotechnologies Reports Second Quarter 2020 Financial Results GlobeNewswire
12:44PM	Did Hedge Funds Make The Right Call On Adaptive Biotechnologies Corporation (ADPT)? Insider Monkey
08:05AM	Adaptive Biotechnologies to Present at the UBS Genomics 2.0 and Medtech Innovations Summit GlobeNewswire
Aug-06-20 09:24AM	Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia GlobeNewswire
Aug-04-20 09:30AM	Adaptive Biotechnologies Launches immunoSEQ T-MAP COVID, First Molecular T Cell Monitoring Tool for SARS-CoV-2 GlobeNewswire
Jul-30-20 06:19AM	Is Adaptive Biotechnologies a Buy? Motley Fool
Jul-28-20 06:04PM	Adaptive Biotechnologies Launches National Clinical Trial to Develop Novel T-Cell Based Diagnostic for Lyme Disease GlobeNewswire
Jul-16-20 12:00PM	Adaptive Biotechnologies (ADPT) Upgraded to Buy: What Does It Mean for the Stock? Zacks -8.58%
Jul-15-20 07:47PM	Adaptive Biotechnologies Announces Pricing of Public Offering of Common Stock GlobeNewswire
Jul-14-20 04:44PM	Adaptive Biotechnologies Announces Proposed Public Offering of Common Stock GlobeNewswire
Jul-09-20 04:29PM	Here's Why Adaptive Biotechnologies Soared 61.7% in the First Half of 2020 Motley Fool
08:05AM	Adaptive Biotechnologies to Report Second Quarter Financial Results on August 10, 2020 GlobeNewswire
Jun-23-20 11:54AM	Hedge Funds Never Been Less Bullish On Adaptive Biotechnologies Corporation (ADPT) Insider Monkey
Jun-17-20 08:56AM	How Adaptive Biotechnologies (ADPT) Stock Stands Out in a Strong Industry Zacks
Jun-15-20 10:27AM	Microsoft (MSFT) and Adaptive Roll Out ImmuneCODE Database Zacks
Jun-11-20 09:00AM	Adaptive Biotechnologies and Microsoft launch groundbreaking ImmuneCODE database to share populationwide immune response to the COVID-19 virus PR Newswire
Jun-08-20 04:03PM	UPDATE Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences GlobeNewswire
Jun-07-20 06:25AM	Goldman Sachs: These 2 Stocks Are Poised to Surge by at Least 30% TipRanks
May-27-20 04:03PM	Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences GlobeNewswire
May-19-20 08:03AM	5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up Zacks
May-18-20 02:47PM	Moderna COVID-19 vaccine data is baby-step in right direction: Expert Yahoo Finance Video
May-14-20 11:51AM	Coronavirus Vaccine Progress Accelerates Yahoo Finance
May-13-20 12:31PM	Adaptive Biotechnologies Corporation (ADPT) Q1 2020 Earnings Call Transcript Motley Fool -6.54%
07:02AM	What's Behind Adaptive Biotechnologies' Q1 Earnings Miss Motley Fool
May-12-20 04:03PM	Adaptive Biotechnologies Reports First Quarter 2020 Financial Results GlobeNewswire
08:06AM	The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings Benzinga
May-11-20 10:57AM	Biotech Stock Q1 Earnings Due on May 12: ADPT, VIR, TPTX Zacks +5.77%
09:57AM	Is a Surprise Coming for Adaptive Biotechnologies (ADPT) This Earnings Season? Zacks
May-08-20 09:09AM	Is a Beat in Store for Sunoco (SUN) This Earnings Season? Zacks
May-06-20 03:06PM	Coronavirus update: U.S. death toll tops 71,000, as Trump backs off plan to wind down pandemic task force MarketWatch
02:50PM	These 23 companies are working on coronavirus treatments or vaccines heres where things stand MarketWatch
12:10PM	Adaptive Biotechnologies and Microsoft Announce New Study of COVID-19 Immune Response Motley Fool
08:19AM	Adaptive, Microsoft to conduct study evaluating T-cells in COVID-19 patients MarketWatch
08:00AM	Adaptive Biotechnologies to Present at the BofA Securities 2020 Healthcare Conference GlobeNewswire
May-05-20 12:00PM	Adaptive Biotechnologies and Microsoft launch virtual ImmuneRACE study to inform novel COVID-19 diagnostics to address unmet needs in testing PR Newswire
Apr-30-20 08:51AM	Remdesivir Progresses on Coronavirus Trial: Pharma Upbeat Zacks
06:39AM	Better Buy: Illumina vs. Adaptive Biotechnologies Motley Fool
Apr-27-20 04:03PM	Adaptive Biotechnologies to Report First Quarter Financial Results on May 12, 2020 GlobeNewswire +10.03%
Apr-20-20 08:15AM	Gilead Increases Enrollment Target, Pharma Rally Continues Zacks +5.58%
Apr-17-20 09:13PM	Adaptive Biotechnologies Collaborations Could Be Vital in Fight Against COVID-19 SmarterAnalyst
12:40PM	4 Healthcare Stocks to Buy For Coronavirus Innovation InvestorPlace
Apr-15-20 04:47PM	Andreas Halvorsen Checks Into Zentalis Pharmaceuticals GuruFocus.com
08:26AM	Pharma Stocks Rally on Sanofi, GSK Coronavirus Vaccine Tie-Up Zacks
Apr-09-20 07:45PM	Adaptive Biotechnologies Expands Executive Leadership Team to Support Development and Commercialization of Clinical Products, including immunoSEQ Dx GlobeNewswire
Apr-07-20 08:35PM	Amgen And Adaptive Biotechnologies To Participate In Webinar On COVID-19 Strategic Collaboration PR Newswire -11.21%
Apr-05-20 10:14AM	With gowns and masks in short supply, researchers test drugs to prevent COVID-19 infections in health care workers MarketWatch
Apr-03-20 10:51AM	Pharma Coronavirus Efforts Continue, Amgen & Incyte Join In Zacks -8.57%
Apr-02-20 07:58PM	Adaptive, Amgen collaborate on development of COVID-19 treatment American City Business Journals
05:50PM	Covid Report: Amgen Pops As Heavyweight Biotech Enters Coronavirus Ring Investor's Business Daily
04:23PM	Biotech Amgen, Adaptive Tech Join Forces on New Coronavirus Drug SmarterAnalyst
04:04PM	Coronavirus update: 1 million global cases, 51,485 deaths and U.S. workers file for benefits in record numbers MarketWatch
12:29PM	Democrats Delay Convention; Italy Infections Slow: Virus Update Bloomberg
09:34AM	Amgen, Adaptive Biotechnologies ink COVID-19 antibody development collaboration MarketWatch
09:00AM	Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19 PR Newswire

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LO FRANCIS	Chief People Officer	Apr 15	Option Exercise	7.80	2,000	15,600	22,604	Apr 16 09:00 PM
LO FRANCIS	Chief People Officer	Apr 15	Sale	43.04	2,000	86,080	20,604	Apr 16 09:00 PM
GRIFFIN MICHELLE RENEE	Director	Apr 14	Option Exercise	7.80	4,500	35,100	6,004	Apr 16 09:00 PM
BALDO LANCE	Chief Medical Officer	Apr 14	Option Exercise	7.80	2,000	15,600	24,894	Apr 16 09:00 PM
GRIFFIN MICHELLE RENEE	Director	Apr 14	Sale	43.41	4,500	195,345	1,504	Apr 16 09:00 PM
BALDO LANCE	Chief Medical Officer	Apr 14	Sale	44.50	2,000	89,000	22,894	Apr 16 09:00 PM
ROBINS CHAD M	CEO and Chairman	Apr 08	Sale	42.45	5,000	212,253	1,748,461	Apr 08 09:00 PM
Cohen Chad M	Chief Financial Officer	Apr 07	Option Exercise	6.32	10,000	63,200	31,604	Apr 08 09:00 PM
Cohen Chad M	Chief Financial Officer	Apr 07	Sale	41.65	10,000	416,504	21,604	Apr 08 09:00 PM
ROBINS CHAD M	CEO and Chairman	Apr 07	Sale	40.79	5,000	203,974	1,753,461	Apr 08 09:00 PM
ADAMS R MARK	Chief Operating Officer	Apr 07	Sale	42.34	3,586	151,831	67,018	Apr 09 03:00 PM
Cohen Chad M	Chief Financial Officer	Apr 06	Option Exercise	6.32	10,000	63,200	31,604	Apr 08 09:00 PM
Cohen Chad M	Chief Financial Officer	Apr 06	Sale	40.95	10,000	409,500	21,604	Apr 08 09:00 PM
ROBINS CHAD M	CEO and Chairman	Apr 06	Sale	42.18	5,000	210,880	1,758,461	Apr 08 09:00 PM
Taylor Stacy L	SVP and General Counsel	Mar 31	Option Exercise	15.04	4,167	62,663	19,203	Apr 02 09:00 PM
Taylor Stacy L	SVP and General Counsel	Mar 31	Sale	40.00	4,167	166,680	15,036	Apr 02 09:00 PM
ROBINS HARLAN S	Chief Scientific Officer	Mar 25	Option Exercise	6.32	5,290	33,433	74,650	Mar 25 09:00 PM
ROBINS HARLAN S	Chief Scientific Officer	Mar 25	Sale	38.30	5,290	202,581	69,360	Mar 25 09:00 PM
ROBINS HARLAN S	Chief Scientific Officer	Mar 24	Option Exercise	6.32	6,395	40,416	75,755	Mar 25 09:00 PM
ROBINS HARLAN S	Chief Scientific Officer	Mar 24	Sale	40.16	6,395	256,844	69,360	Mar 25 09:00 PM
ROBINS HARLAN S	Chief Scientific Officer	Mar 23	Option Exercise	6.32	7,790	49,233	77,150	Mar 25 09:00 PM
ROBINS HARLAN S	Chief Scientific Officer	Mar 23	Sale	41.93	7,790	326,635	69,360	Mar 25 09:00 PM
ROBINS CHAD M	CEO and Chairman	Mar 19	Sale	41.97	5,000	209,852	1,763,461	Mar 19 09:00 PM
Palaniappan Jyoti	SVP, Diagnostics, immunoSEQ Dx	Mar 18	Option Exercise	22.55	16,052	361,973	25,210	Mar 19 09:00 PM
Palaniappan Jyoti	SVP, Diagnostics, immunoSEQ Dx	Mar 18	Sale	43.58	16,052	699,560	9,158	Mar 19 09:00 PM
ROBINS CHAD M	CEO and Chairman	Mar 18	Sale	42.55	5,000	212,753	1,768,461	Mar 19 09:00 PM
ROBINS CHAD M	CEO and Chairman	Mar 17	Sale	44.16	5,000	220,811	1,773,461	Mar 19 09:00 PM
GRIFFIN MICHELLE RENEE	Director	Mar 16	Option Exercise	7.80	1,500	11,700	3,004	Mar 17 07:00 PM
GRIFFIN MICHELLE RENEE	Director	Mar 16	Sale	47.00	1,500	70,500	1,504	Mar 17 07:00 PM
GRIFFIN MICHELLE RENEE	Director	Mar 15	Option Exercise	7.80	4,500	35,100	6,004	Mar 17 07:00 PM
BENZENO SHARON	Chief Business Development Off	Mar 15	Option Exercise	31.71	1,354	42,935	24,248	Mar 17 07:00 PM
LO FRANCIS	Chief People Officer	Mar 15	Option Exercise	7.80	2,000	15,600	22,604	Mar 17 07:00 PM
GRIFFIN MICHELLE RENEE	Director	Mar 15	Sale	41.75	4,500	187,863	1,504	Mar 17 07:00 PM
BENZENO SHARON	Chief Business Development Off	Mar 15	Sale	41.69	1,354	56,451	22,894	Mar 17 07:00 PM
LO FRANCIS	Chief People Officer	Mar 15	Sale	41.83	2,000	83,656	20,604	Mar 17 07:00 PM
Cohen Chad M	Chief Financial Officer	Mar 10	Option Exercise	6.32	10,000	63,200	31,604	Mar 12 08:00 PM
GOEL DAVID E.	Director	Mar 10	Sale	41.96	56,000	2,349,701	12,309,090	Mar 10 07:45 PM
Cohen Chad M	Chief Financial Officer	Mar 10	Sale	42.54	10,000	425,400	21,604	Mar 12 08:00 PM
Cohen Chad M	Chief Financial Officer	Mar 09	Option Exercise	6.32	10,000	63,200	31,064	Mar 10 07:00 PM
GOEL DAVID E.	Director	Mar 09	Sale	40.52	250,000	10,131,220	12,365,090	Mar 10 07:45 PM
Cohen Chad M	Chief Financial Officer	Mar 09	Sale	40.24	10,000	402,425	21,064	Mar 10 07:00 PM
HERSHBERG ROBERT	Director	Mar 08	Option Exercise	0.45	2,000	900	2,000	Mar 10 07:00 PM
HERSHBERG ROBERT	Director	Mar 08	Option Exercise	0.45	2,000	900	3,504	Mar 10 07:00 PM
GOEL DAVID E.	Director	Mar 08	Sale	39.50	500,000	19,747,906	12,615,090	Mar 10 07:45 PM
HERSHBERG ROBERT	Director	Mar 08	Sale	44.56	2,000	89,120	0	Mar 10 07:00 PM
HERSHBERG ROBERT	Director	Mar 08	Sale	44.56	2,000	89,120	1,504	Mar 10 07:00 PM
Pellini Michael J	Director	Mar 01	Option Exercise	6.55	20,000	131,000	20,000	Mar 03 07:00 PM
BENZENO SHARON	Chief Business Development Off	Mar 01	Option Exercise	6.72	6,771	45,475	6,771	Mar 03 07:00 PM
RUBINSTEIN JULIE	President	Mar 01	Option Exercise	6.55	15,000	98,250	15,000	Mar 03 07:00 PM
Pellini Michael J	Director	Mar 01	Sale	57.80	20,000	1,156,000	0	Mar 03 07:00 PM
BENZENO SHARON	Chief Business Development Off	Mar 01	Sale	57.62	6,771	390,143	0	Mar 03 07:00 PM
RUBINSTEIN JULIE	President	Mar 01	Sale	58.32	15,000	874,743	0	Mar 03 07:00 PM
Taylor Stacy L	SVP and General Counsel	Feb 26	Option Exercise	7.01	2,812	19,720	4,112	Mar 01 08:00 PM
RUBINSTEIN JULIE	President	Feb 26	Option Exercise	6.55	15,000	98,250	15,000	Mar 01 09:00 PM
Taylor Stacy L	SVP and General Counsel	Feb 26	Sale	55.53	2,812	156,138	1,300	Mar 01 08:00 PM
RUBINSTEIN JULIE	President	Feb 26	Sale	56.23	15,000	843,450	0	Mar 01 09:00 PM
RUBINSTEIN JULIE	President	Feb 25	Option Exercise	6.55	14,675	96,121	14,675	Feb 26 06:00 PM
RUBINSTEIN JULIE	President	Feb 25	Sale	56.18	14,675	824,427	0	Feb 26 06:00 PM
RUBINSTEIN JULIE	President	Feb 24	Option Exercise	6.55	15,000	98,250	15,000	Feb 26 06:00 PM
RUBINSTEIN JULIE	President	Feb 24	Sale	57.78	15,000	866,629	0	Feb 26 06:00 PM
RUBINSTEIN JULIE	President	Feb 23	Option Exercise	6.55	15,000	98,250	15,000	Feb 24 09:00 PM
RUBINSTEIN JULIE	President	Feb 23	Sale	55.45	15,000	831,790	0	Feb 24 09:00 PM
RUBINSTEIN JULIE	President	Feb 22	Option Exercise	6.55	15,000	98,250	15,000	Feb 24 09:00 PM
RUBINSTEIN JULIE	President	Feb 22	Sale	59.71	15,000	895,621	0	Feb 24 09:00 PM
RUBINSTEIN JULIE	President	Feb 19	Option Exercise	6.55	15,000	98,250	15,000	Feb 22 07:00 PM
BENZENO SHARON	Chief Business Development Off	Feb 19	Option Exercise	6.27	416	2,608	416	Mar 03 07:00 PM
RUBINSTEIN JULIE	President	Feb 19	Sale	62.29	15,000	934,365	0	Feb 22 07:00 PM
BENZENO SHARON	Chief Business Development Off	Feb 19	Sale	61.20	416	25,459	0	Mar 03 07:00 PM
RUBINSTEIN JULIE	President	Feb 18	Option Exercise	6.55	15,000	98,250	15,000	Feb 19 08:00 PM
RUBINSTEIN JULIE	President	Feb 18	Sale	60.92	15,000	913,817	0	Feb 19 08:00 PM
RUBINSTEIN JULIE	President	Feb 17	Option Exercise	6.55	15,000	98,250	15,000	Feb 19 08:00 PM
RUBINSTEIN JULIE	President	Feb 17	Sale	62.05	15,000	930,819	0	Feb 19 08:00 PM
LO FRANCIS	Chief People Officer	Feb 16	Option Exercise	7.80	2,000	15,600	2,000	Feb 17 08:01 PM
RUBINSTEIN JULIE	President	Feb 16	Option Exercise	6.55	15,000	98,250	15,000	Feb 17 08:01 PM
Taylor Stacy L	SVP and General Counsel	Feb 16	Option Exercise	31.71	16,250	515,288	17,550	Feb 17 08:01 PM
BENZENO SHARON	Chief Business Development Off	Feb 16	Option Exercise	31.71	16,250	515,288	16,250	Feb 17 08:01 PM
HERSHBERG ROBERT	Director	Feb 16	Option Exercise	0.45	2,000	900	3,504	Feb 17 08:00 PM
GRIFFIN MICHELLE RENEE	Director	Feb 16	Option Exercise	7.80	6,000	46,800	7,504	Feb 16 08:26 PM
LO FRANCIS	Chief People Officer	Feb 16	Sale	65.45	2,000	130,900	0	Feb 17 08:01 PM
RUBINSTEIN JULIE	President	Feb 16	Sale	65.25	15,000	978,750	0	Feb 17 08:01 PM
Taylor Stacy L	SVP and General Counsel	Feb 16	Sale	64.64	16,250	1,050,327	1,300	Feb 17 08:01 PM
BENZENO SHARON	Chief Business Development Off	Feb 16	Sale	64.64	16,250	1,050,381	0	Feb 17 08:01 PM
HERSHBERG ROBERT	Director	Feb 16	Sale	65.45	2,000	130,900	1,504	Feb 17 08:00 PM
GRIFFIN MICHELLE RENEE	Director	Feb 16	Sale	65.08	6,000	390,480	1,504	Feb 16 08:26 PM
RUBINSTEIN JULIE	President	Feb 12	Option Exercise	6.55	15,000	98,250	15,000	Feb 17 08:01 PM
RUBINSTEIN JULIE	President	Feb 12	Sale	65.98	15,000	989,682	0	Feb 17 08:01 PM
RUBINSTEIN JULIE	President	Feb 11	Option Exercise	6.55	15,000	98,250	15,000	Feb 12 08:00 PM
RUBINSTEIN JULIE	President	Feb 11	Sale	63.28	15,000	949,149	0	Feb 12 08:00 PM
RUBINSTEIN JULIE	President	Feb 10	Option Exercise	6.55	15,000	98,250	15,000	Feb 12 08:00 PM
ROBINS CHAD M	CEO and Chairman	Feb 10	Sale	62.76	10,000	627,648	1,709,780	Feb 10 09:00 PM
RUBINSTEIN JULIE	President	Feb 10	Sale	62.96	15,000	944,405	0	Feb 12 08:00 PM
RUBINSTEIN JULIE	President	Feb 09	Option Exercise	6.47	15,000	97,100	15,000	Feb 10 09:00 PM
ROBINS CHAD M	CEO and Chairman	Feb 09	Sale	62.55	10,000	625,526	1,719,780	Feb 10 09:00 PM
RUBINSTEIN JULIE	President	Feb 09	Sale	62.41	15,000	936,091	0	Feb 10 09:00 PM
RUBINSTEIN JULIE	President	Feb 08	Option Exercise	6.32	15,000	94,800	15,000	Feb 10 09:00 PM
ROBINS CHAD M	CEO and Chairman	Feb 08	Sale	61.61	10,000	616,149	1,729,780	Feb 10 09:00 PM
RUBINSTEIN JULIE	President	Feb 08	Sale	62.10	15,000	931,442	0	Feb 10 09:00 PM
RUBINSTEIN JULIE	President	Feb 05	Option Exercise	6.32	15,000	94,800	15,000	Feb 08 09:00 PM
RUBINSTEIN JULIE	President	Feb 05	Sale	59.96	15,000	899,328	0	Feb 08 09:00 PM
RUBINSTEIN JULIE	President	Feb 04	Option Exercise	6.32	15,000	94,800	15,000	Feb 05 06:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience